Enterococcus faecalis overcomes foreign body-mediated inflammation to establish urinary tract infections

Infection and Immunity

Volumn 81, Issue 1, 2013, Pages 329-339

  Guiton, Pascale S ^a,b   Hannan, Thomas J ^a   Ford, Bradley ^a,b   Caparon, Michael G ^a,b   Hultgren, Scott J ^a,b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; AMINOGUANIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; SILICONE;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BIOFILM; BLADDER; CATHETER ASSOCIATED URINARY TRACT INFECTION; CATHETER INFECTION; CONTROLLED STUDY; CYSTITIS; DRUG EFFICACY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; FEMALE; FOREIGN BODY; HISTOPATHOLOGY; INFLAMMATION; MEDIATOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SILASTIC TUBE; SILICONE PROSTHESIS; URINARY CATHETER; URINARY TRACT INFECTION;

ANIMALS; BIOFILMS; CATHETERS; CYTOKINES; EDEMA; ENTEROCOCCUS FAECALIS; FEMALE; FOREIGN BODIES; GLUCOCORTICOIDS; GRAM-POSITIVE BACTERIAL INFECTIONS; INFLAMMATION; MICE; MICE, INBRED C57BL; MYELOID CELLS; NEUTROPHILS; URINARY BLADDER; URINARY CATHETERIZATION; URINARY TRACT INFECTIONS;

EID: 84871858863     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00856-12     Document Type: Article

References (99)

1. Hartstein AI, Garber SB, Ward TT, Jones SR, Morthland VH. 1981. Nosocomial urinary tract infection: a prospective evaluation of 108 catheterized patients. Infect. Control 2:380-386.
2. Tambyah PA, Halvorson KT, Maki DG. 1999. A prospective study of pathogenesis of catheter-associated urinary tract infections. Mayo Clin. Proc. 74:131-136.
3. Warren JW. 2001. Catheter-associated urinary tract infections. Int. J. Antimicrob. Agents 17:299-303.
4. Norden CW. 1968. Study of urinary infections by catheterization. N. Engl.J. Med. 278:966-967.
5. Garibaldi RA, Burke JP, Britt MR, Miller MA, Smith CB. 1980. Meatal colonization and catheter-associated bacteriuria. N. Engl. J. Med. 303: 316-318.
6. Parsons CL. 1986. Pathogenesis of urinary tract infections. Bacterial adherence, bladder defense mechanisms. Urol. Clin. North Am. 13:563-568.
7. Peychl L, Zalud R. 2008. Changes in the urinary bladder caused by short-term permanent catheter insertion. Cas. Lek. Cesk. 147:325-329. (In Czech.)
8. Saint S, Chenoweth CE. 2003. Biofilms and catheter-associated urinary tract infections. Infect. Dis. Clin. North Am. 17:411-432.
9. Hashmi S, Kelly E, Rogers SO, Gates J. 2003. Urinary tract infection in surgical patients. Am. J. Surg. 186:53-56.
10. Delnay KM, Stonehill WH, Goldman H, Jukkola AF, Dmochowski RR. 1999. Bladder histological changes associated with chronic indwelling uri-nary catheter. J. Urol. 161:1106-1109.
11. Vaidyanathan S, Mansour P, Ueno M, Yamazaki K, Wadhwa M, Soni BM, Singh G, Hughes PL, Watson ID, Sett P. 2002. Problems in early diagnosis of bladder cancer in a spinal cord injury patient: report of a case of simultaneous production of granulocyte colony stimulating factor and parathyroid hormone-related protein by squamous cell carcinoma of uri-nary bladder. BMC Urol. 2:8. doi:10.1186/1471-2490-2-8.
12. Vaidyanathan S, Soni BM, Bingley J, Brown E, Markey S. 2002. Prevention of pressure sore caused by indwelling urinary catheters. Spinal Cord 40:489.
13. Kurosaka Y, Ishida Y, Yamamura E, Takase H, Otani T, Kumon H. 2001. A non-surgical rat model of foreign body-associated urinary tract infection with Pseudomonas aeruginosa. Microbiol. Immunol. 45:9-15.
14. Kaufman JM, Fam B, Jacobs SC, Gabilondo F, Yalla S, Kane JP, Rossier AB. 1977. Bladder cancer and squamous metaplasia in spinal cord injury patients. J. Urol. 118:967-971.
15. Jacobs SC, Kaufman JM. 1978. Complications of permanent bladder catheter drainage in spinal cord injury patients. J. Urol. 119:740-741.
16. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006 -2007. Infect. Control Hosp. Epidemiol. 29:996 -1011.
17. Nielsen HV, Guiton PS, Kline KA, Port GC, Pinkner JS, Neiers F, Normark S, Henriques-Normark B, Caparon MG, Hultgren SJ. 2012. The metal ion-dependent adhesion site motif of the Enterococcus faecalis EbpA pilin mediates pilus function in catheter-associated urinary tract infection. mBio 3(4):e00177-00112. doi:10.1128/mBio.00177-12.
18. Guiton PS, Hung CS, Hancock LE, Caparon MG, Hultgren SJ. 2010. Enterococcal biofilm formation and virulence in an optimized murine model of foreign body-associated urinary tract infections. Infect. Immun. 78:4166 -4175.
19. Ingersoll MA, Kline KA, Nielsen HV, Hultgren SJ. 2008. G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity. Cell. Microbiol. 10:2568-2578.
20. Hong W, Juneau RA, Pang B, Swords WE. 2009. Survival of bacterial biofilms within neutrophil extracellular traps promotes nontypeable Haemophilus influenzae persistence in the chinchilla model for otitis media. J. Innate Immun. 1:215-224.
21. Juneau RA, Pang B, Weimer KE, Armbruster CE, Swords WE. 2011. Nontypeable Haemophilus influenzae initiates formation of neutrophil extracellular traps. Infect. Immun. 79:431-438.
22. Thiennimitr P, Winter SE, Winter MG, Xavier MN, Tolstikov V, Huseby DL, Sterzenbach T, Tsolis RM, Roth JR, Baumler AJ. 2011. Intestinal inflammation allows Salmonella to use ethanolamine to compete with the microbiota. Proc. Natl. Acad. Sci. U. S. A. 108:17480-17485.
23. Murray BE, An FY, Clewell DB. 1988. Plasmids and pheromone response of the beta-lactamase producer Streptococcus (Enterococcus) faecalis HH22. Antimicrob. Agents Chemother. 32:547-551.
24. Murray BE, Singh KV, Ross RP, Heath JD, Dunny GM, Weinstock GM. 1993. Generation of restriction map of Enterococcus faecalis OG1 and investigation of growth requirements and regions encoding biosynthetic function. J. Bacteriol. 175:5216-5223.
25. Saria A, Lundberg JM. 1983. Evans blue fluorescence: quantitative and morphological evaluation of vascular permeability in animal tissues. J. Neurosci. Methods 8:41-49.
26. Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE. 2008. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J. Leukoc. Biol. 83:64-70.
27. Snider RM, Constantine JW, Lowe JA III, Longo KP, Lebel WS, Woody HA, Drozda SE, Desai MC, Vinick FJ, Spencer RW, Hess HJ. 1991. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 251:435- 437.
28. Snider RM, Longo KP, Drozda SE, Lowe JA III, Leeman SE. 1991. Effect of CP-96,345, a nonpeptide substance P receptor antagonist, on salivation in rats, Proc. Natl. Acad. Sci. U. S. A. 88:10042-10044.
29. McLean S, Ganong A, Seymour PA, Snider RM, Desai MC, Rosen T, Bryce DK, Longo KP, Reynolds LS, Robinson G, Schmidt AW, Siok C, Heym J. 1993. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J. Pharmacol. Exp. Ther. 267:472-479.
30. McLean S, Snider RM, Desai MC, Rosen T, Bryce DK, Longo KP, Schmidt AW, Heym J. 1993. CP-99,994, a nonpeptide antagonist of the tachykinin NK1 receptor. Regul. Pept. 46:329-331.
31. Abraham P, Rabi S, Kulothungan P. 2009. Aminoguanidine, selective nitric oxide synthase inhibitor, ameliorates cyclophosphamide-induced hemorrhagic cystitis by inhibiting protein nitration and PARS activation. Urology 73:1402-1406.
32. Abraham P, Rabi S, Selvakumar D. 2009. Protective effect of aminoguanidine against oxidative stress and bladder injury in cyclophosphamide-induced hemorrhagic cystitis in rat. Cell Biochem. Funct. 27:56-62.
33. Griffiths MJ, Messent M, MacAllister RJ, Evans TW. 1993. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br. J. Pharmacol. 110:963-968.
34. Stroncek DF, Skubitz KM, McCullough JJ. 1990. Biochemical characterization of the neutrophil-specific antigen NB1. Blood 75:744-755.
35. Kau AL, Martin SM, Lyon W, Hayes E, Caparon MG, Hultgren SJ. 2005. Enterococcus faecalis tropism for the kidneys in the urinary tract of C57BL/6J mice. Infect. Immun. 73:2461-2468.
36. Guiton PS, Hung CS, Kline KA, Roth R, Kau AL, Hayes E, Heuser J, Dodson KW, Caparon MG, Hultgren SJ. 2009. Contribution of autolysin and sortase A during Enterococcus faecalis DNA-dependent biofilm development. Infect. Immun. 77:3626-3638.
37. Nishii H, Nomura M, Fujimoto N, Matsumoto T. 2006. Up-regulation of interleukin-6 gene expression in cyclophosphamide-induced cystitis in mice: an in situ hybridization histochemical study. Int. J. Urol. 13:1339 -1343.
38. Olivar T, Laird JM. 1999. Cyclophosphamide cystitis in mice: behavioural characterisation and correlation with bladder inflammation. Eur. J. Pain 3:141-149.
39. Bjorling DE, Wang ZY, Bushman W. 2011. Models of inflammation of the lower urinary tract. Neurourol. Urodyn. 30:673-682.
40. Geppetti P, Nassini R, Materazzi S, Benemei S. 2008. The concept of neurogenic inflammation. BJU Int. 101(Suppl 3):2-6.
41. Eglezos A, Giuliani S, Viti G, Maggi CA. 1991. Direct evidence that capsaicin-induced plasma protein extravasation is mediated through tachykinin NK1 receptors. Eur. J. Pharmacol. 209:277-279.
42. Trevisani M, Campi B, Gatti R, Andre E, Materazzi S, Nicoletti P, Gazzieri D, Geppetti P. 2007. The influence of alpha1-adrenoreceptors on neuropeptide release from primary sensory neurons of the lower uri-nary tract. Eur. Urol. 52:901-908.
43. Chavez A, Smith M, Mehta D. 2011. New insights into the regulation of vascular permeability. Int. Rev. Cell Mol. Biol. 290:205-248.
44. Andersson PT, Persson CG. 1988. Developments in anti-asthma glucocorticoids. Agents Actions Suppl. 23:239-260.
45. Bowden JJ, Schoeb TR, Lindsey JR, McDonald DM. 1994. Dexamethasone and oxytetracycline reverse the potentiation of neurogenic inflammation in airways of rats with Mycoplasma pulmonis infection. Am. J. Respir. Crit. Care Med. 150:1391-1401.
46. Brain SD, Newbold P, Kajekar R. 1995. Modulation of the release and activity of neuropeptides in the microcirculation. Can. J. Phys. Pharmacol. 73:995-998.
47. Frode-Saleh TS, Calixto JB, Medeiros YS. 1999. Analysis of the inflammatory response induced by substance P in the mouse pleural cavity. Peptides 20:259-265.
48. Huang HT, Haskell A, McDonald DM. 1989. Changes in epithelial secretory cells and potentiation of neurogenic inflammation in the trachea of rats with respiratory tract infections. Anat. Embryol. 180:325-341.
49. Kingery WS, Castellote JM, Maze M. 1999. Methylprednisolone prevents the development of autotomy and neuropathic edema in rats, but has no effect on nociceptive thresholds. Pain 80:555-566.
50. Piedimonte G, McDonald DM, Nadel JA. 1990. Glucocorticoids inhibit neurogenic plasma extravasation and prevent virus-potentiated extravasation in the rat trachea. J. Clin. Invest. 86:1409-1415.
51. Piedimonte G, Pickles RJ, Lehmann JR, McCarty D, Costa DL, Boucher RC. 1997. Replication-deficient adenoviral vector for gene transfer potentiates airway neurogenic inflammation. Am. J. Respir. Cell Mol. Biol. 16: 250-258.
52. Tafler R, Herbert MK, Schmidt RF, Weis KH. 1993. Small reduction of capsaicin-induced neurogenic inflammation in human forearm skin by the glucocorticoid prednicarbate. Agents Actions 38(Spec No):C31-C34.
53. Lundberg JM, Martling CR, Saria A, Folkers K, Rosell S. 1983. Cigarette smoke-induced airway oedema due to activation of capsaicin-sensitive vagal afferents and substance P release. Neuroscience 10:1361-1368.
54. Martling CR, Lundberg JM. 1988. Capsaicin sensitive afferents contribute to acute airway edema following tracheal instillation of hydrochloric acid or gastric juice in the rat. Anesthesiology 68:350 -356.
55. Newton R. 2000. Molecular mechanisms of glucocorticoid action: what is important? Thorax 55:603-613.
56. Lan NC, Karin M, Nguyen T, Weisz A, Birnbaum MJ, Eberhardt NL, Baxter JD. 1984. Mechanisms of glucocorticoid hormone action. J. Steroid Biochem. 20:77-88.
57. Norman M, Hearing SD. 2002. Glucocorticoid resistance-what is known? Curr. Opin. Pharmacol. 2:723-729.
58. Chung KF, Godard P, Adelroth E, Ayres J, Barnes N, Barnes P, Bel E, Burney P, Chanez P, Connett G, Corrigan C, de Blic J, Fabbri L, Holgate ST, Ind P, Joos G, Kerstjens H, Leuenberger P, Lofdahl CG, McKenzie S, Magnussen H, Postma D, Saetta M, Salmeron S, Sterk P. 1999. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/ Therapy-Resistant Asthma. Eur. Respir. J. 13:1198 -1208.
59. Dalakas MC. 2011. Inflammatory myopathies: management of steroid resistance. Curr. Opin. Neurol. 24:457-462.
60. Park SJ, Shin JI. 2011. Complications of nephrotic syndrome. Korean J. Pediatr. 54:322-328.
61. Ito K, Chung KF, Adcock IM. 2006. Update on glucocorticoid action and resistance. J. Allergy Clin. Immunol. 117:522-543.
62. Lu YS, Lien HC, Yeh PY, Yeh KH, Kuo ML, Kuo SH, Cheng AL. 2005. Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors. World J. Gastroenterol. 11:6373-6380.
63. Strickland I, Kisich K, Hauk PJ, Vottero A, Chrousos GP, Klemm DJ, Leung DY. 2001. High constitutive glucocorticoid receptor beta in neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids. J. Exp. Med. 193:585-593.
64. Goleva E, Li LB, Eves PT, Strand MJ, Martin RJ, Leung DY. 2006. Increased glucocorticoid receptor beta alters steroid response in glucocorticoid-insensitive asthma. Am. J. Respir. Crit. Care Med. 173:607-616.
65. Leendertse M, Willems RJ, Giebelen IA, van den Pangaart PS, Bonten MJ, van der Poll T. 2009. The acute-phase response impairs host defence against Enterococcus faecium peritonitis. Immunology 128:e335-342.
66. Kobayashi Y. 2006. Neutrophil infiltration and chemokines. Crit. Rev. Immunol. 26:307-316.
67. Leendertse M, Willems RJ, Giebelen IA, Roelofs JJ, Bonten MJ, van der Poll T. 2009. Neutrophils are essential for rapid clearance of Enterococcus faecium in mice. Infect. Immun. 77:485-491.
68. Fazal N, Shelip A, Siddiqui E, Ali A, Azim AC, Al-Ghoul WM. 2012. Differential effector responses by circulating/blood and tissue/peritoneal neutrophils following burn combined with Enterococcus faecalis infection. FEMS Immunol. Med. Microbiol. 64:191-204.
69. Tsuda Y, Shigematsu K, Kobayashi M, Herndon DN, Suzuki F. 2008. Role of polymorphonuclear neutrophils on infectious complications stemming from Enterococcus faecalis oral infection in thermally injured mice. J. Immunol. 180:4133-4138.
70. Ma Z, Wang Y, Zhu X, Zhang C, Li S, Jin L, Shen Y, Haapasalo M. 2011. Role of polymorphonuclear neutrophils in the clearance of Enterococcus faecalis derived from saliva and infected root canals. J. Endod. 37:346 -352.
71. Leendertse M, Willems RJ, Giebelen IA, van den Pangaart PS, Wiersinga WJ, de Vos AF, Florquin S, Bonten MJ, van der Poll T. 2008. TLR2-dependent MyD88 signaling contributes to early host defense in murine Enterococcus faecium peritonitis. J. Immunol. 180:4865-4874.
72. Guiton PS, Cusumano CK, Kline KA, Dodson KW, Han Z, Janetka JW, Henderson JP, Caparon MG, Hultgren SJ. 2012. Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice. Antimicrob. Agents Che-mother. 56:4738 -4745.
73. Rakita RM, Vanek NN, Jacques-Palaz K, Mee M, Mariscalco MM, Dunny GM, Snuggs M, Van Winkle WB, Simon SI. 1999. Enterococcus faecalis bearing aggregation substance is resistant to killing by human neutrophils despite phagocytosis and neutrophil activation. Infect. Immun. 67:6067-6075.
74. Vanek NN, Simon SI, Jacques-Palaz K, Mariscalco MM, Dunny GM, Rakita RM. 1999. Enterococcus faecalis aggregation substance promotes opsonin-independent binding to human neutrophils via a complement receptor type 3-mediated mechanism. FEMS Immunol. Med. Microbiol. 26:49 -60.
75. Teng F, Jacques-Palaz KD, Weinstock GM, Murray BE. 2002. Evidence that the enterococcal polysaccharide antigen gene (epa) cluster is widespread in Enterococcus faecalis and influences resistance to phagocytic killing of E. faecalis. Infect. Immun. 70:2010 -2015.
76. Shon W, Lim S, Bae KS, Baek S, Lee W. 2005. The expression of alpha4 integrins by human polymorphonuclear neutrophils in response to sonicated extracts of Enterococcus faecalis. J. Endod. 31:369 -372.
77. Shigematsu K, Asai A, Kobayashi M, Herndon DN, Suzuki F. 2009. Enterococcus faecalis translocation in mice with severe burn injury: a pathogenic role of CCL2 and alternatively activated macrophages (M2aMphi and M2cMphi). J. Leukoc. Biol. 86:999 -1005.
78. La Carbona S, Sauvageot N, Giard JC, Benachour A, Posteraro B, Auffray Y, Sanguinetti M, Hartke A. 2007. Comparative study of the physiological roles of three peroxidases (NADH peroxidase, alkyl hydroperoxide reductase and thiol peroxidase) in oxidative stress response, survival inside macrophages and virulence of Enterococcus faecalis. Mol. Microbiol. 66:1148 -1163.
79. Verneuil N, Maze A, Sanguinetti M, Laplace JM, Benachour A, Auffray Y, Giard JC, Hartke A. 2006. Implication of (Mn) superoxide dismutase of Enterococcus faecalis in oxidative stress responses and survival inside macrophages. Microbiology 152:2579 -2589.
80. Baldassarri L, Bertuccini L, Creti R, Filippini P, Ammendolia MG, Koch S, Huebner J, Orefici G. 2005. Glycosaminoglycans mediate invasion and survival of Enterococcus faecalis into macrophages. J. Infect. Dis. 191:1253-1262.
81. Verneuil N, Sanguinetti M, Le Breton Y, Posteraro B, Fadda G, Auffray Y, Hartke A, Giard JC. 2004. Effects of the Enterococcus faecalis hypR gene encoding a new transcriptional regulator on oxidative stress response and intracellular survival within macrophages. Infect. Immun. 72:4424 -4431.
82. Baldassarri L, Bertuccini L, Ammendolia MG, Cocconcelli P, Arciola CR, Montanaro L, Creti R, Orefici G. 2004. Receptor-mediated endocytosis of biofilm-forming Enterococcus faecalis by rat peritoneal macrophages. Indian J. Med. Res. 119(Suppl):131-135.
83. Baldassarri L, Cecchini R, Bertuccini L, Ammendolia MG, Iosi F, Arciola CR, Montanaro L, Di Rosa R, Gherardi G, Dicuonzo G, Orefici G, Creti R. 2001. Enterococcus spp. produces slime and survives in rat peritoneal macrophages. Med. Microbiol. Immunol. 190:113-120.
84. Sussmuth SD, Muscholl-Silberhorn A, Wirth R, Susa M, Marre R, Rozdzinski E. 2000. Aggregation substance promotes adherence, phagocytosis, and intracellular survival of Enterococcus faecalis within human macrophages and suppresses respiratory burst. Infect. Immun. 68:4900 -4906.
85. Gentry-Weeks CR, Karkhoff-Schweizer R, Pikis A, Estay M, Keith JM. 1999. Survival of Enterococcus faecalis in mouse peritoneal macrophages. Infect. Immun. 67:2160 -2165.
86. Hendrickx AP, van Luit-Asbroek M, Schapendonk CM, van Wamel WJ, Braat JC, Wijnands LM, Bonten MJ, Willems RJ. 2009. SgrA, a nidogen-binding LPXTG surface adhesin implicated in biofilm formation, and EcbA, a collagen binding MSCRAMM, are two novel adhesins of hospital-acquired Enterococcus faecium. Infect. Immun. 77:5097-5106.
87. Mohamed JA, Huang DB. 2007. Biofilm formation by enterococci. J. Med. Microbiol. 56:1581-1588.
88. Mohamed JA, Huang W, Nallapareddy SR, Teng F, Murray BE. 2004. Influence of origin of isolates, especially endocarditis isolates, and various genes on biofilm formation by Enterococcus faecalis. Infect. Immun. 72: 3658 -3663.
89. Nallapareddy SR, Singh KV, Sillanpaa J, Garsin DA, Hook M, Erlandsen SL, Murray BE. 2006. Endocarditis and biofilm-associated pili of Enterococcus faecalis. J. Clin. Invest. 116:2799 -2807.
90. Kosmidis CI, Chandrasekar PH. 2012. Management of gram-positive bacterial infections in patients with cancer. Leuk. Lymphoma 53:8 -18.
91. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309 -317.
92. Sastry V, Brennan PJ, Levy MM, Fishman N, Friedman AL, Naji A, Barker CF, Brayman KL. 1995. Vancomycin-resistant enterococci: an emerging pathogen in immunosuppressed transplant recipients. Transplant. Proc. 27:954 -955.
93. Bonten MJ, Willems R, Weinstein RA. 2001. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect. Dis. 1:314 -325.
94. Warren JW, Muncie HL, Jr, Hall-Craggs M. 1988. Acute pyelonephritis associated with bacteriuria during long-term catheterization: a prospective clinicopathological study. J. Infect. Dis. 158:1341-1346.
95. Trautner BW, Darouiche RO. 2004. Role of biofilm in catheter-associated urinary tract infection. Am. J. Infect. Control 32:177-183.
96. Donelli G, Guaglianone E. 2004. Emerging role of Enterococcus spp in catheter-related infections: biofilm formation and novel mechanisms of antibiotic resistance. J. Vasc. Access 5:3-9.
97. Donlan RM. 2001. Biofilms and device-associated infections. Emerg. Infect. Dis. 7:277-281.
98. Dickinson GM, Bisno AL. 1989. Infections associated with indwelling devices: infections related to extravascular devices. Antimicrob. Agents Chemother. 33:602-607.
99. Dickinson GM, Bisno AL. 1989. Infections associated with indwelling devices: concepts of pathogenesis; infections associated with intravascular devices. Antimicrob. Agents Chemother. 33:597-601.